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http:WHAT THIS PAPER ADDS
Most patients with BCS complicated by IVC thrombosis have a chronic disease course. Manifestations of
thrombus formation are often concealed by the clinical manifestations of IVC obstruction. Therefore, the time at
which thrombus formation occurs (acute, subacute, or chronic) is not clear. Thrombus formation is a dynamic
process. Fresh thrombus evolves gradually (not suddenly) into old thrombus, so there is a type of thrombotic
state (mixed), between fresh and old thrombus. Based on imaging features and transcatheter aspiration, IVC
thrombus can be divided into fresh, mixed, and old types. Endovascular treatment strategies should be adopted
according to the properties of thrombus, which can result in excellent long-term patency.Objectives: The aim of this study was to evaluate the strategy and long-term outcomes of endovascular
treatment of BuddeChiari syndrome (BCS) complicated by inferior vena cava (IVC) thrombosis.
Methods: The treatment strategy and outcomes of BCS complicated by IVC thrombosis were retrospectively
evaluated in a single-center study. The treatment was aimed at the IVC thrombus, not hepatic vein occlusion. All
133 patients with BCS complicated by IVC thrombosis from February 2003 to March 2013 underwent
endovascular treatment. For the fresh thrombus group (n ¼ 75) recanalization was performed after transcatheter
thrombolysis with urokinase. For the mixed thrombus group (n ¼ 19) a small balloon pre-dilation of the IVC was
performed ﬁrst, followed by transcatheter thrombolysis using urokinase and a large balloon dilation of the IVC.
For the old thrombus group (n ¼ 39) a large balloon dilation or/and stent placement was performed directly. Pre-
and post-treatment follow-ups were recorded.
Results: The endovascular treatment was successful in 131 out of 133 patients (98.5%). Thirty seven patients had
synchronous hepatic vein occlusion. The incidence of serious complications was 4.5% (6/133). Symptomatic
pulmonary embolism occurred in three cases, cerebral hemorrhage in two, and cardiac tamponade in one. The
cumulative 1-, 5-, and 10-year primary patency rate was 96.3%, 84.0%, and 64.6%, respectively. The cumulative
1-, 5-, and 10-year secondary patency rate was 99.0%, 96.1% and 91.3%, respectively. Segmental occlusion of the
IVC and duration of anticoagulant therapy less than 6 months were independent risk factors for reocclusion.
Conclusions: For patients with BCS complicated by IVC thrombosis, an individualized treatment strategy based on
the property of the thrombus can result in excellent long-term patency.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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BuddeChiari syndrome (BCS) refers to occlusion of any part
of the outﬂow tract of the hepatic vein, from small hepatic
veins to the conﬂuence of the inferior vena cava (IVC) and
right atrium.1 In western countries, BCS mainly involves
occlusion of the hepatic vein.2 In China, it mainly involves
occlusion of the IVC with or without hepatic vein occlusion.3
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Methods for treating BCS complicated by IVC thrombosis
include the use of warfarin, transcatheter thrombolysis
using urokinase, stent placement, and stent ﬁlter place-
ment.5e7 However, there have been only few studies in
which thrombi are categorized into fresh thrombus, mixed
thrombus, and old thrombus, which are then treated
accordingly. In addition, until now the long-term outcome
of BCS complicated by IVC thrombosis after endovascular
treatment has remained unclear. In this study the endo-
vascular treatment strategies for patients with BCS
complicated by IVC thrombosis and their long-term out-
comes are reported. The large number of patients included
in this study made it possible to establish routine treatment
methods and to determine the risk factors that might
predict reocclusion.
Table 1. Clinical parameters in 133 patients with BuddeChiari syndrome complicated by inferior vena cava thrombosis.
Variable Fresh thrombus group Mixed thrombus group Old thrombus group
No. 75 19 39
Sex
Male 48 12 20
Female 27 7 19
Age (years) 49 (18e76) 46 (35e78) 47 (18e75)
Laboratory tests
Prothrombin time (s) 15.3 (11.4e25.9) 16 (13.2e19.9) 15.3 (10.4e21)
INR 1.25 (1e2.4) 1.3 (1e1.6) 1.2 (0.9e1.9)
GGT (U/L) 59 (7e381) 83 (36e297) 89 (30e279)
Alkaline phosphatase (U/L) 99 (52e249) 111 (75e245) 93 (52e194)
Albumin (g/L) 36.1 (22.9e48.6) 32.1 (21.3e45) 34.6 (25.7e47.4)
TB (mmol/L) 29.1 (8.9e191) 33.9 (13.4e164.3) 28 (4.4e136)
Creatinine (mmol/L) 60 (23e232) 62 (56e145) 71 (46e103)
BUN (mmol/L) 5 (2.6e21.1) 4.5 (2.6e11) 5 (2.9e12.1)
Alpha-fetoprotein >20 ng/mL 4 1 1
ChildePugh class
A 53 9 19
B 13 7 15
C 9 3 5
ChildePugh score 7 (5e13) 8 (6e11) 7 (5e12)
Clichy score 5.1 (2.7e8.2) 5 (3.3e7.7) 4.9 (3.2e7.5)
Rotterdam score 1.1 (0.02e1.8) 1.1 (0.03e1.6) 1.1 (0.02e1.7)
Note. GGT ¼ g-glutamyl transpeptidase; TB ¼ total bilirubin; BUN ¼ blood urea nitrogen; INR ¼ international normalized ratio.
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Patient information
This was a retrospective study. All protocols were approved
by the Ethics Committee of the Afﬁliated Hospital of Xuzhou
Medical College (Jiangsu Province, China). All the partici-
pating patients gave informed consent before endovascular
treatment.
From February 2003 to March 2013, a total of 133 pa-
tients (80 males and 53 females) with primary BCS
complicated by IVC thrombosis were included in this study.
The average age was 48 (18e78) years. Patients with con-
traindications to anticoagulation, severe hepatic failure or
heart failure were excluded. All 133 patients were diag-
nosed using color Doppler ultrasound, magnetic resonance
angiography and/or computer tomography angiography, IVC
angiography, and aspiration of the IVC thrombus. Among
them, there were 75 cases of fresh thrombus, 19 cases of
mixed thrombus, and 39 cases of old thrombus. All 133
patients had the symptoms and signs of IVC obstruction for
1e240 months. Initial patient demographic information
before endovascular treatment was obtained from medical
records for this retrospective analysis (Table 1).Procedures
The treatment steps for IVC occlusion complicated by
thrombus are illustrated in Fig. 1 and are as the follows:
Step 1. IVC angiography and transcatheter aspiration. A 6F
catheter sheath was placed in the femoral vein, and a 5F
pigtail catheter was advanced into the IVC for contrast in-
jection. The pigtail catheter was withdrawn and a 6F Judkins
right guiding catheter (Cordis Corp., Hialeah, FL, USA) wasadvanced to the level of the IVC thrombus. The catheter
was pushed back and forth and simultaneously rotated to
facilitate aspiration of the thrombus. Selection of strategies
for the subsequent treatments depended mainly on gross
examination of the captured thrombus: (a) mixed thrombi,
containing a large amount of gray-white thrombi and a
small amount of dark red thrombi (Fig. 2A,B), were treated
with a small balloon pre-dilation of the IVC (see Step 2); (b)
fresh thrombus, that was dark red and soft, was treated
with transcatheter thrombolysis (see Step 3); and (c) when
no thrombus or only a small amount of white thrombus was
obtained from the aspiration, it was determined to be an
old thrombus and balloon dilation of the IVC was performed
(see Step 4).
Step 2. Small balloon pre-dilation of the IVC. The jugular
veinwas punctured and a 6F catheter sheathwas placed. A 5F
angiographic catheter (Cordis Corp.) was advanced to the
proximal end of the IVC to perform angiography. A
steel needle with a curved head (China Patent No.
201120361170.4, the principal advantage of which is that the
head-end can be curved to accommodate the shape of IVC),
was advanced through the 5F angiographic catheter and
penetrated the IVC occlusion from the top to the bottomend.
The needle was withdrawn and a guidewire with length
260 cm and diameter 0.035 inches was advanced through the
5F angiographic catheter to the distal end of IVC. Next, the 5F
catheter was withdrawn, and a smaller balloon with a
diameter of 8 or 10mmand a length of 40mm (CookMedical,
Bjaeverskov, Denmark) was advanced along the guidewire to
dilate the occluded segment of the IVC (Fig. 2CeE). If the IVC
occlusion could not be penetrated through the jugular vein,
penetration of the occluded segment of the IVC from its distal
to proximal end was performed through the femoral vein.
Figure 1. Treatment steps for inferior vena cava occlusion complicated by thrombus.
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5F thrombolytic catheter (Cook Medical, Bloomington, IN,
USA)was inserted via the femoral vein or internal jugular vein,
and the segment with side holes was located inside the
thrombus. A pulse-spray infusion was used to inject 20 mL of
saline and 10million units of urokinase once every 3e6 hours.
The thrombolytic catheter was kept in place, and angiography
was performed 2 days later. Thrombolysis treatment was
terminated if: (a) the thrombus was completely lysed; (b)
during thrombolysis serious complications such as organ
bleeding occurred; and (c) there was no change in the
thrombus 2 days after thrombolysis treatment. During
thrombolysis, 5000 U of low-molecular-weight heparin was
injected subcutaneously every 12 hours. Thrombolysis was
administered on a common ward. Fibrinogen, prothrombin
time, and activated partial thromboplastin time were tested
every 2 days during thrombolytic therapy.
Step 4. Large balloon dilation of the IVC. After thrombolytic
treatment of mixed thrombus (Fig. 2FeI) and fresh
thrombus (Fig. 3) or in patients with old thrombus (Fig. 4Ae
C), a large balloon dilation of the IVC was performed. The
balloons used were 20, 25, 26, or 28 mm in diameter and
40 mm in length (Optimed, Ettlingen, Germany) or 30 mm
in diameter and 50 mm in length (Cook Medical).
Step 5. Self-expandable IVC stent placement. This was
considered when: (a) after large balloon dilation of the IVC,
luminal diameter retraction was greater than 50%; (b) after
large balloon dilation of the IVC, the pressure gradient be-
tween the IVC and the right atrium was higher than 15 cm
H2O (1 cmH2O ¼ 0.098 kPa); or (c) there were emboli in the
IVC and stent compression was needed. A stainless steel Z-type IVC stent with a diameter of 28 or 30 mm and a length
of 70e90 mm (Shenyang Yongtong Technology Co., Ltd.,
Shengyang, China) was used.Post-treatment observations and follow-up
After treatment, all patients received subcutaneous low-
molecular-weight heparin for 4e7 days, followed by
warfarin sodium for 12e24 months. The international
normalized ratio (INR) was maintained at 2e3. Follow-up
included determination of symptoms and signs, color
Doppler ultrasound, and laboratory test results (coagulation
function, liver and kidney function). Follow-up was gener-
ally performed at 1, 3, 6, and 12 months after treatment
and yearly thereafter. If the patient felt discomfort, follow-
up examination was performed at any time upon request.Statistical analysis
All statistical analyses were performed using SPSS, version
16.0 (SPSS Inc., Chicago, IL, USA). Quantitative data were
expressed as median (range), and between-group compari-
sons were performed using an independent-sample t-test or
paired-sample t-test. Count data were expressed as a ratio (or
percentage), and the chi-square test was used for compari-
sons. KaplaneMeier curveswere used to calculate cumulative
primary patency rates and cumulative secondary patency
rates. A Cox proportional hazards regression model was used
to analyze predictable risk factors for reocclusion. The factors
that were statistically signiﬁcant in univariate analysis
(p < .05) were further tested with multivariate analysis. A
differencewith p< .05was considered statistically signiﬁcant.
Figure 2. Images of a 58-year-old female with BuddeChiari syndrome complicated by mixed inferior vena cava (IVC) thrombus. (A)
Cavography showed IVC occlusion accompanied by thrombus and collateral vessels. (B) Mixed thrombus contained both a large amount of
gray-white thrombi and a small amount of dark red thrombi. (C) Cavography through the jugular vein demonstrated the occlusion site at
the proximal end of IVC. (D) Transjugular placement of a small balloon (diameter 8 mm) to dilate the occluded segment. (E) After small
balloon dilation, cavography demonstrated partial opening of the IVC. (F) After thrombolytic treatment, cavography demonstrated
complete dissolution of the thrombus. (GeH) A 28 mm diameter balloon was advanced through the femoral vein to dilate the IVC. (I) After
large balloon dilation of the IVC, angiography showed that the lumen was clear, and the collateral vessels had disappeared.
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The overall success
The success rate of endovascular treatment in this study
was 98.5% (131/133). The mean pressure gradient between
the IVC and the right atrium dropped from 26 (range 18e
33) cmH2O before treatment to 8 (range 3e15) cmH2O after
treatment (t ¼ 106.2, p < .05). Of the 74 patients with a
fresh thrombus, the thrombus was completely lysed in 71
patients and partially lysed in three. Of the 19 patients with
mixed thrombus, the thrombus was completely lysed in 14
patients and partially lysed in ﬁve (chi square ¼ 6.9,
p < .05). Thirty-seven patients had synchronous hepatic
vein occlusion, the accessory hepatic vein was patent in 16
patients, and one main hepatic vein was recanalized suc-
cessfully in 21 patients. In 131 patients, the clinical mani-
festations were improved at discharge.Technical failure
Technical failure occurred in two patients (1.5%). One pa-
tient with a fresh IVC thrombus developed a subarachnoid
hemorrhage after the ﬁrst transcatheter injection of 10
million units of urokinase. After 1 month, the patient had
recovered from the brain hemorrhage. The second patient
had an old, widely calciﬁed IVC thrombus. After IVC pene-
tration and placement of a 20-mm balloon for dilation, the
balloon ruptured. No further endovascular treatment was
performed.Procedure-related complications
Six (4.5%) patients had serious complications. Three pa-
tients sustained symptomatic pulmonary embolisms after
large balloon dilation and were treated successfully using
urokinase. Two patients had cerebral hemorrhage.
Figure 3. Images of a 43-year-old male patient with BuddeChiari syndrome complicated by fresh inferior vena cava (IVC) thrombus. (A)
Cavography showed IVC occlusion accompanied by a large amount of thrombus. (B) Fresh thrombus contained dark red and soft thrombi.
(C) After thrombolytic treatment, cavography showed that the thrombus was completely lysed. (D) A 30 mm diameter balloon was
advanced through the femoral vein to dilate the IVC occlusion. (E) After balloon dilation, the IVC was patent.
Figure 4. Images of a 69-year-old male patient with BuddeChiari syndrome complicated by old inferior vena cava (IVC) thrombus. (A)
Cavography showed IVC occlusion with old thrombus. (B) Balloon (28 mm in diameter) dilation of the IVC occlusion through the internal
jugular vein. (C) After balloon dilation of IVC occlusion, angiography showed a patent lumen. The position and morphology of the embolus
inside appeared unchanged. The hemiazygos vein had disappeared. (D) Post-treatment follow-up at 13 months by ultrasound showed no
IVC thrombus and a patent lumen.
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Figure 5. Post-treatment inferior vena cava cumulative patency
rates. Cox proportional hazards regression analysis.
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previously mentioned). In the second patient, a cerebellar
hemorrhage occurred at the end of thrombolytic treatment.
Anticoagulation and thrombolytic treatment were stopped
after IVC balloon dilation. Two months later, the patient had
completely recovered. One patient developed cardiac
tamponade secondary to vascular manipulations. Pericar-
dial drainage was achieved using a percutaneous catheter.
There were three (2.3%) patients with mild complications.
Two patients had a hematoma of the femoral vein puncture
site and one had a hematoma of the jugular vein puncture
site. Both patients responded to local compression.
Patency
The average duration of follow-up in the 131 patients was 46
(range 3e132) months. Ten patients were lost to follow up.
Among the remaining 121 patients, the clinical manifestations
had improved signiﬁcantly in 104 patients and deteriorated in
17 (Table 2). The duration of anticoagulant therapy in 41 pa-
tients was less than 6 months. Among the 35 patients in the
old thrombus group, 21 had a complete resolution of their
thrombus (Fig. 4D). In 14 patients, the thrombus was reduced
in size compared with pretreatment. Color Doppler ultra-
sound showed IVC lumenpatency in 105 patients (86.8%), and
IVC reocclusion in 16 patients (13.2%). The reocclusion rate
was 14.5% (10/69), 11.8% (2/17), and 11.4% (4/35) in the
fresh, mixed, and old thrombus groups respectively (chi
square ¼ 0.2, p ¼ .9). In 16 patients with reocclusion, eight
received another thrombolytic treatment before balloon
dilation, and IVC patency was again achieved. Four patients
received another balloon dilation and stent placement, and
IVC patency was achieved as well. Endovascular treatment
was not completed in four patients at their request. The cu-
mulative 1-, 5-, and 10-year primary patency rate was 96.3%,
84.0% and 64.6%, respectively. The cumulative 1-, 5-, and 10-
year secondary patency rate was 99.0%, 96.1% and 91.3%,
respectively (Fig. 5). Univariate analysis showed that alpha-
fetoprotein (>20 ng/mL), prothrombin time (<17 seconds),
INR (<1.5), segmental occlusion of IVC (>1 cm), and antico-
agulant therapy <6 months were the risk factors for reoc-
clusion, whereas gender, age, liver function, kidney function,
absence of thrombolytic therapy (for old thrombosis), ChildeTable 2. Comparison of clinical manifestations before and after endovas
Symptoms and signs Fresh thrombus group
(n ¼ 69) No. (%)
PP 49 (3e132) M
Weakness 55 (79.7) 5 (7.3)
Abdominal distention 27 (39.1) 3 (4.4)
Ascites 49 (71) 2 (2.9)
Jaundice 44 (63.8) 6 (8.7)
Hepatomegaly/splenomegaly 51 (73.9) 5 (7.3)
Gastrointestinal bleeding 7 (10.1) 1 (1.5)
Distended abdominal veins 58 (84.1) 5 (7.3)
Lower extremity edema 33 (47.8) 2 (2.9)
Leg pigmentation 16 (23.2) 2 (2.9)
Leg ulcer 13 (18.8) 0 (0)
Note. PP ¼ pre-procedure; M ¼ months.Pugh class, ChildePugh score, Clichy score, and Rotterdam
score were not correlated with post-treatment reocclusion.
Multivariate analysis showed that segmental occlusion of the
IVC (risk ratio [RR] 26.1; 95% conﬁdence interval [CI] 1.5e471)
and anticoagulant treatment duration <6 months (RR 16.7;
95% CI 1.3e221.5) were independent risk factors for reoc-
clusion.Two patients died of liver failure during postoperative
follow-up at 18 and 26 months. One patient died of hepatic
cell carcinoma 15 months following treatment.DISCUSSION
In the present study, IVC thrombi were ﬁrstly divided into
fresh, mixed, and old types, and different endovascular
treatment strategies were adopted accordingly. A long-term
follow-up of a large number of cases was carried out and
satisfactory therapeutic outcomes were achieved.
Mixed thrombi include a large amount of white thrombus
and a small amount of red thrombus. White thrombus is
rich in ﬁbers and retracts more than red thrombus, and is,
therefore, not easily lysed.8 After small balloon pre-dilation
of the IVC, blood ﬂow towards the heart was restored,cular treatment in 121 treated patients during long-term follow-up.
Mixed thrombus group
(n ¼ 17) No. (%)
Old thrombus group
(n ¼ 35) No. (%)
PP 41 (6e112) M PP 43 (5e121) M
11 (64.7) 2 (11.8) 14 (40) 2 (5.7)
9 (52.9) 1 (5.9) 11 (31.4) 3 (8.6)
9 (52.9) 0 (0) 16 (45.7) 1 (2.9)
14 (82.4) 2 (11.8) 22 (62.9) 2 (5.7)
8 (47.1) 2 (11.8) 18 (51.4) 4 (11.4)
4 (23.5) 0 (0) 2 (5.7) 0 (0)
17 (100) 1 (5.9) 28 (80) 4 (11.4)
11 (64.7) 1 (5.9) 7 (20) 0 (0)
6 (35.3) 1 (5.9) 15 (42.9) 2 (5.7)
3 (17.7) 0 (0) 9 (25.7) 0 (0)
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In our study, none of the patients in the mixed thrombus
group developed clinically signiﬁcant pulmonary embolism.
This indicates that small balloon pre-dilation is safe. In this
study, the diameter of small balloons was 8e10 mm and
after small balloon pre-dilation of the IVC, the lumen was
signiﬁcantly narrowed by more than 50%. This observation
was similar to an IVC ﬁlter used to treat deep vein throm-
bosis of the lower limbs,9 which could stop large thrombi.
Even if the smaller fragments fell off, they did not result in
symptomatic pulmonary embolism and subsequent throm-
bolytic therapy gradually lysed these fragments. There are
several methods for treating BCS complicated by fresh IVC
thrombus. They include thrombolytic therapy with drugs
such as urokinase, rtPA, and agitation thrombolysis.6,10 In
contrast to the previous reports, we successfully treated 74
patients with BCS complicated by fresh IVC thrombus using
transcatheter thrombus aspiration in combination with
pulse-spray thrombolysis. Consistent with our results,
Yamada et al.11 reported that pulse-spray thrombolysis was
a safe and effective approach for treating acute deep
venous thrombosis.
Methods used to treat BCS complicated by old IVC
thrombus included thrombolytic therapy before IVC dila-
tion, stent ﬁlter placement, and thrombolytic therapy after
IVC dilation.12,13 In contrast to previous studies, 38 patients
were successfully treated with direct large balloon dilation
of the IVC and/or stent placement, followed by anticoagu-
lant therapy with warfarin. Because old thrombus is ﬁrmly
and closely adherent to the vessel wall and does not fall off,
pulmonary embolism does not occur after opening the IVC.
In addition, after IVC blood ﬂow is restored to normal, the
old thrombus will gradually undergo autolysis.
Previous studies have shown that balloon dilation and/or
stent placement can achieve satisfactory long-term out-
comes in BCS patients.14e16 A study by Han et al.14 showed
that after vessel recanalization in BCS patients, the 1-, 5-,
and 10-year cumulative primary patency rate was 95%, 77%
and 58%, respectively, and the 1-, 5-, and 10-year cumula-
tive secondary patency rate was 97%, 90% and 86%,
respectively. The 1-, 5-, and 10-year cumulative primary
patency rate and cumulative secondary patency rate
observed in this study were similar to those reported by
Han et al. Previous studies have shown that factors such as
segmental occlusion of the IVC and no postoperative anti-
coagulant therapy are highly correlated with reocclu-
sion.15,16 In this study segmental occlusion of the IVC and
duration of anticoagulant therapy <6 months were highly
correlated with reocclusion. A minority of patients did not
achieve the anticoagulant effect, probably because they did
not take the warfarin as prescribed. This might be one of
the reasons why the duration of anticoagulant therapy was
less than 6 months.CONCLUSION
Patients with BCS complicated by IVC thrombosis should be
managed on an individualized basis, according to theproperty of their thrombus (fresh, mixed, or old). Our re-
sults have shown that endovascular treatment for patients
with BCS complicated by IVC thrombosis is safe and
feasible, and can achieve excellent long-term patency.
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